CMKLR1 and lung disorder: In this study, we established CMKLR1 as a biomarker of MDMφ enriched in patients with fibrotic lung diseases, and demonstrated the accuracy of CMKLR1-targeted PET to noninvasively monitor the accumulation of MDMφ and predict the severity of future fibrosis in the murine model of bleomycin-induced lung injury.